glp 1 trials Discover How GLP-1 Are Not One-Size-Fit-All Frontiers | The agony and

Drago F et al

BPC-157 reduces inflammatory cytokine expression in injury models and achieves anti-inflammatory effects at the cellular level without globally suppressing the immune system

Modulating NRF2 in Disease: Timing is Everything

Where they overlap and where they don't Complementary Mechanism Targets Target Origin BPC-157 Gastric juice protein fragment (15 amino acids) TB-500 Thymosin Beta-4 fragment (LKKTETQ region) Target Primary action BPC-157 Local tissue repair signaling TB-500 Systemic cell migration and mobilization Target Angiogenesis BPC-157 VEGF upregulation, NO pathway TB-500 Endothelial migration, VEGF crosstalk Target Cell migration BPC-157 Indirect, via growth factors TB-500 Direct (G-actin sequestering) Target Best-evidence tissue BPC-157 Tendon, gut, gastric mucosa (preclinical) TB-500 Cardiac, corneal, skin (preclinical + early human T4) Target Reported in vivo half-life BPC-157 ~4 hours (animal estimates) TB-500 ~23 days (animal estimates) Half-life figures are pharmacokinetic estimates from animal studies

Juonala M, Viikari JS, Laitinen T, Marniemi J, Helenius H, Ronnemaa T, Raitakari OT

Are nail changes really linked to psoriatic arthritis